文拉法辛与帕罗西汀治疗抑郁症临床效果观察.docVIP

文拉法辛与帕罗西汀治疗抑郁症临床效果观察 　　[摘要] 目的 探讨文拉法辛缓释剂和帕罗西汀治疗抑郁症的效果。 方法 选择本院 2012年6月～2013年3月收治的抑郁症患者60例，随机分为A、B两组，其中A组给予文拉法辛缓释剂治疗，B组给予帕罗西汀治疗，两组均治疗2个月，采用汉密尔顿抑郁量表（HAMD）、临床疗效总体评价量表（CGI）评价治疗效果，观察两组治疗不良反应情况。 结果 两组治疗后HAMD、CGI量表评分均较治疗前降低（P0.05）；治疗1、4、8周时两组CGI评分差异均无统计学意义（P0.05）；治疗后两组有效率比较，差异无统计学意义（P0.05）。两组治疗过程中均出现口干、便秘、恶心、心电图异常等不良反应，但组间差异无统计学意义，且不良反应经对症处理后均减轻或消失，未影响治疗。 结论 文拉法辛缓释剂和帕罗西汀治疗抑郁症的疗效无明显差异，安全性均较高，但文拉法辛起效时间较帕罗西汀短，值得应用。 　　[关键词] 抑郁症；文拉法辛；帕罗西汀；疗效；不良反应 　　[中图分类号] R971+.43 [文献标识码] A [文章编号] 1674-4721（2013）11（b）-0069-02 　　The clinical efficacy of venlafaxine extended release formulations and paroxetine in treatment of depression 　　DENG YU 　　Pharmacy Department of Brain Hospital in Hunan Province，Changsha 410007，China 　　[Abstract] Objective To investigate efficacy and safety of venlafaxine extended release formulations and paroxetine in treatment of depression. Methods 60 patients with depression from June 2012 to March 2013 in our hospital were randomly divided into two groups， patients in group A were given venlafaxine extended release formulations treatment， patients in group B were given paroxetine treatment， they were all treated for two months， and then the Hamilton depression rating scale （HAMD）， the overall clinical rating scale （CGI） were used to evaluate the therapeutic effects， and adverse reactions were observed. Results After treatment， HAMD， CGI score were lower than that before treatment （P0.05）； After 1，4，8 weeks treatment CGI scores between two groups were not statistically significant （P0.05）； and treatment efficiency of two groups compared， the difference was not significant （P0.05）. During the treatment， mouth dry ， constipation， nausea， abnormal electrocardiogram and other adverse reactions were all found in two groups， but the difference was not significant， and the adverse reactions were reduced or disappeared after symptomatic treatment， and did not affect the treatment.Conclusion Venlafaxine extended release formulations and paroxetine in the treatment of